ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION

ACTG A5142 - HIV-1 感染的 III 期药物治疗

• 批准号: 7377007
• 负责人: JEFFERY L MEIER
• 金额: $ 1.33万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377007
• 关键词: ACTG; A5142; PHASE; III; DRUG

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current guidelines for the initial treatment of HIV-1 infection provide a number of options to subjects and providers. Durable improvements in virologic and immunologic parameters are observed in the majority of naive subjects for each of the recommended regimens. As newer treatment strategies and drugs become available it is important to critically assess their role in the management of HIV-1 infection. This study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second-generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen for the initial treatment of HIV-1 infection.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。 HIV-1感染初始治疗的当前指南为受试者和提供者提供了许多选择。对于每个推荐方案，大多数幼稚的受试者都可以观察到病毒学和免疫学参数的持久改进。随着新的治疗策略和药物的可用，重要的是要批判性地评估其在HIV-1感染管理中的作用。这项研究将研究lopinavir/Ritonavir（利托纳维尔增强的，第二代蛋白酶抑制剂）的使用方案，非核苷的逆转录酶抑制剂（NNRTI）的基于核苷的逆转录酶抑制剂（NNRTI），以及核苷的远期方案HIV-1感染的治疗。